 Home > Medical News > Medicines Company News > InnoCare will present the latest research data of Gunagratinib in the treatment of cholangiocarcinoma at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium

InnoCare will present the latest research data of Gunagratinib in the treatment of cholangiocarcinoma at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium

 Last Update: 2023-02-03
 Source: Internet
 Author: User

Tags

cancer explained

research poster size

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

InnoCare, a biomedical high-tech company, (HKEx: 09969; SSE code: 688428) announced on January 5 that the company will publish the latest research data
on the treatment of cholangiocarcinoma with the FGFR inhibitor Gunagratinib (ICP-192) at the 2023 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI).

The 2023 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI) will be held
online and in-person in San Francisco, USA, January 19-21, 2023.
ASCO GI is the world's authoritative academic exchange event in the field of gastrointestinal cancer, which will showcase innovative scientific research results, strategies and multidisciplinary research methods
in the treatment, research and care of gastrointestinal cancer.

Poster display

: The highly selective irreversible FGFR inhibitor Gunagratinib in previously treated patients with locally advanced or metastatic FGFR gene abnormalities with cholangiocarcinoma: a phase IIa dose expansion study

Summary code: 572

Sub-venue: Poster venue B: Pancreatic cancer, small bowel cancer and hepatobiliary cancer

When: January 20, 12:00 PM - 1:30 PM US time

: Professor Guo Ye

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.